How are energy investors positioned?
Vitale Lucas, the Chief People & Business Operations Officer (CP&BOO) of Orthofix Medical (TASE:BLWV) Inc. (NASDAQ:OFIX), recently executed a sale of company stock valued at $71,164. The transaction involved the disposal of 4,287 shares at a price of $16.60 per share. This sale was conducted on March 18, 2025, as part of a pre-existing sell-to-cover requirement to satisfy tax withholding obligations related to the settlement of restricted stock units. According to InvestingPro data, the stock trades with relatively low volatility and maintains strong liquidity with a current ratio of 2.57x, though analysts don’t expect profitability this year.
Following this transaction, Lucas retains ownership of 135,317 shares in the company, which includes 123,894 restricted stock units that have been previously reported. The transaction was carried out without any discretionary decision-making by Lucas, in accordance with a mandate from the Compensation and Talent Development Committee of Orthofix Medical’s Board of Directors. Get access to 6 more exclusive InvestingPro Tips and comprehensive financial analysis in our detailed Pro Research Report.
In other recent news, Orthofix Medical Inc. reported fourth-quarter earnings with revenue reaching $215.7 million, a 7.6% increase from the previous year, surpassing analyst expectations of $212.7 million. The company’s adjusted EBITDA also exceeded forecasts, coming in at $23.9 million against the anticipated $22.6 million. Despite this positive performance, Orthofix’s revenue guidance for fiscal year 2025, set between $818 million and $826 million, fell short of the Street’s projection of $847 million due to the discontinuation of certain product lines. In regulatory news, Orthofix received FDA 510(k) clearance for its TrueLok™ Elevate Transverse Bone Transport System, which is now available in a limited market release in the U.S. and select international markets. Additionally, the company expanded its Board of Directors with the appointment of Vickie Capps, a finance expert with extensive board experience. Analyst firm BTIG maintained a Neutral rating on Orthofix, while Canaccord Genuity initiated coverage with a Buy rating and a price target of $24.00, reflecting optimism about the company’s strategic initiatives post-merger with SeaSpine. These developments highlight Orthofix’s ongoing efforts in innovation and strategic growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.